Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.

ABSTRACT:

Background

Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective.

Methods

Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized tri

SUBMITTER: Riccio E 

PROVIDER: S-EPMC7035732 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature